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Abstract
Background: The prevalence of obesity is rising. Obesity can lead to cardiovascular and ventilatory complications through
multiple mechanisms. Cardiac and pulmonary function in asymptomatic subjects and the effect of structured dietary
programs on cardiac and pulmonary function is unclear.
Objective: To determine lung and cardiac function in asymptomatic obese adults and to evaluate whether weight loss
positively affects functional parameters.
Methods: We prospectively evaluated bodyplethysmographic and echocardiographic data in asymptomatic subjects
undergoing a structured one-year weight reduction program.
Results: 74 subjects (32 male, 42 female; mean age 42612 years) with an average BMI 42.567.9, body weight
123.7624.9 kg were enrolled. Body weight correlated negatively with vital capacity (R =20.42, p,0.001), FEV1 (R =20.497,
p,0.001) and positively with P 0.1 (R = 0.32, p = 0.02) and myocardial mass (R = 0.419, p= 0.002). After 4 months the study
subjects had significantly reduced their body weight (226.0611.8 kg) and BMI (28.963.8) associated with a significant
improvement of lung function (absolute changes: vital capacity +5.567.5% pred., p,0.001; FEV1+9.868.3% pred., p,0.001,
ITGV+16.4616.0% pred., p,0.001, SR tot 217.4641.5% pred., p,0.01). Moreover, P0.1/Pimax decreased to 47.7% (p,0.01)
indicating a decreased respiratory load. The change of FEV1 correlated significantly with the change of body weight (R =2
0.31, p= 0.03). Echocardiography demonstrated reduced myocardial wall thickness (20.0860.2 cm, p= 0.02) and improved
left ventricular myocardial performance index (20.1660.35, p = 0.02). Mitral annular plane systolic excursion (+0.14, p = 0.03)
and pulmonary outflow acceleration time (AT +26.65641.3 ms, p = 0.001) increased.
Conclusion: Even in asymptomatic individuals obesity is associated with abnormalities in pulmonary and cardiac function
and increased myocardial mass. All the abnormalities can be reversed by a weight reduction program.
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Introduction
The worldwide prevalence of obesity is rising [1]. Obesity leads
to increasing morbidity [1,2,3] and mortality [4], a loss of potential
and quality adjusted years of life and is a major economic
challenge for health care systems [5]. It contributes to an
increasing risk for a large variety of diseases including arterial
hypertension, diabetes mellitus, dyslipidemia, coronary artery
disease, stroke, cancer and obstructive sleep apnea [1]. A negative
influence of obesity on diastolic and systolic ventricular function
was reported as well as ‘‘obesity cardiomyopathy’’ [6,7]. Obesity is
also an independent predictor for the development of pulmonary
hypertension in patients with diastolic left ventricular dysfunction
[8]. In patients with obstructive sleep apnea, body weight
correlates with pulmonary artery pressure [9]. Further, obesity
can cause obesity hypoventilation syndrome (OHS) [10,11] and
may contribute to pulmonary hypertension in these patients
[10,11]. In subjects with OHS and severe PH, pulmonary artery
pressure is correlated to body mass index, pCO2 and reduced
power of breathing [11]. However, not all obese subjects develop
PLOS ONE | www.plosone.org 1 September 2014 | Volume 9 | Issue 9 | e107480
obesity hypoventilation syndrome [12], and neither all patients
with OHS are affected by pulmonary hypertension [13]. The
cardiac and pulmonary function in asymptomatic obese subjects is
not well studied.
Obesity can affect pulmonary function in multiple ways. Static
lung volumes and maximal power of breathing is reduced. Airway
resistance and work of breathing is increased [14,15]. A
contributory role of these abnormalities to the pathophysiology
of asthma and pulmonary arterial hypertension in obese patients is
likely [16–24]. Humoral interactions, e.g. leptin resistance
contributing to hypoventilation [29], and a major role of
adiponectine in the pathophysiology of PAH and asthma have
been discussed [25–28]. However, it remains unclear whether
body fat contributes to functional abnormalities in the cardiopul-
monary system via an underlying systemic inflammatory process
or if ventilation and pulmonary circulation are only influenced by
the mechanical influences of increased body fat [30]. Because
interactions and the sequence of events remain unclear, it is of
great interest to determine possible early events on the path to
clinically evident disease. It is unclear whether obesity has an
impact on lung and cardiac function in asymptomatic subjects.
Interventional programs are promising tools to reduce obesity
associated morbidity and mortality. The benefit of surgically
induced weight loss on lung and cardiac function has been
convincingly demonstrated [13,31]. In contrast, there are few
studies that have assessed the effect of structured weight reduction
programs on pulmonary function and echocardiographically
measured cardiac function, blood pressure and pulmonary
hemodynamics assessed by echocardiography or right heart
catheterization and they have shown conflicting results [32–34].
Especially the effect of dietary induced weight loss on lung and
cardiac function of asymptomatic subjects has not been studied.
We studied and report the effect of a weight reduction program
which is based on the use of a formula diet on lung and cardiac
function. It includes a supervision of all participants by a
multidisciplinary team of physicians, dietary specialists, physio-
therapists and psychologists specialized in the long-term treatment
of obese patients.
Objective
We aimed to determine the influence of body weight on lung
and cardiac function in asymptomatic obese adults and to evaluate
the effect of a structured weight reduction program on lung and
cardiac function.
We show that even in asymptomatic individuals obesity is
associated with cardiopulmonary functional abnormalities and
these abnormalities can be reversed by weight reduction.
Methods
In a prospective observational study lung function tests and
echocardiography were performed in 74 subjects who underwent
an interdisciplinary 52-week weight reduction program. The
structure of this weight loss program addressing people with a
BMI.30 kg/m2 was described before [35]. It consists of a one-
week run-in-period, a twelve week fasting period followed by an
eight week changeover and a 31-week stabilization period. The
study was approved by our local Ethics Committee. Baseline data
were collected during the one-week run-in-period. A follow-up
examination 16 weeks after start of the dietary program was
offered to all patients. The time point four weeks after completion
of the fasting period was chosen to analyze the effect of potential
maximum weight loss on cardiopulmonary function.
Study subjects
Study subjects were recruited from 83 consecutive subjects who
registered for the structured dietary program at Medical Mission
Hospital between January 2009 and May 2012. 74 patients gave
written informed consent and were studied at baseline and at
follow-up 12 weeks later. Nine patients declined to participate.
Eight patients who had stopped the dietary program during the
first twelve weeks were not examined at the 16-week follow-up.
Some patients did not complete all measurements of the follow-up
examination. Only patients with data available from both baseline
and three month follow-up period were included for analysis of
changes in each parameter.
Procedures
Bodyplethysmography including measurement of transfer factor
(Masterscreen Body/Diff CareFusion, Germany) was performed
according to the European Respiratory Society Statement [36].
Inspiratory mouth pressures were measured as described [37–41].
Echocardiography (Vivid7, GE Medical Systems, Solingen,
Germany) was performed to measure left and right ventricular
function, myocardial mass, systolic right ventricular pressure, right
ventricular outflow tract acceleration time and to rule out cardiac
shunts and significant valve pathology as recommended [42,43].
We further analyzed the available data of Bioelectrical Impedance
analysis, which was introduced into the weight reduction program
during the study. Bioelectrical impedance analysis (BIA 2000-S,
Data Input GmbH Darmstadt, Germany) was performed as
recommended and according to the manufacturers guideline
[44,45]. The same diagnostic tests used at baseline were performed
at the follow-up.
Statistical analysis
Statistical analysis was done using the program SPSS, Version
19.0 (IBM SPSS Statistics). Data are presented as mean and
standard deviation. Baseline and follow-up values were compared
and significance was evaluated by the paired t-test and assumed if
p-value was ,0.05. Pearson correlation of the parameters was
calculated. Statistical significance was assumed if p-value was ,
0.05.
Results
Anthropometric data and bioelectrical impedance
analysis
The subjects were selected as shown in figure 1. Table 1
summarizes the anthropometric data of the 74 individuals at
baseline. The results of the bioelectric impedance analysis at
baseline are shown in Table S1. The cohort comprised 32 males
and 42 females. Mean age was 43612 years. The subjects
presented with severe obesity with a mean body-mass-index
(BMI) of 42.567.9 kg/m2 and a mean body weight of
123.7624.9 kg. The waist-to-hip ratio was 0.9460.1. Body fat
was 55.8616.6 kg and 44.468.4% respectively. Resting metabolic
rate was 1756.46293.9 kcal. Body fluid was calculated with
50.7611.5 l. The majority of subjects presented without dyspnea:
NYHA I = 68/74, NYHA II = 6/74, NYHA III = 0/74, NYHA
IV = 0/74. Seven of the 74 subjects were smokers. Comorbidities
are shown in table S2.
Baseline data
The results of the pulmonary function tests are summarized in
table 2. Mean expiratory flow 25, intrathroracic gas volume
(ITGV), total lung capacity and transfer factor of the lung
Cardiopulmonary Function in Obesity and Effect of Weight Loss
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measured by the single breath method (TLCO-SB) were mildly
decreased compared to the, not weight specific normal values,
published by Quanjer for a cohort of subjects aged 18–70 years
with a height of 1.45–1.95 m [36]. P0.1 and P0.1/Pimax were
increased compared to a cohort with normal weight reported by
Koch et al [38] and non weight-specific reference values proposed
by the German Airway League [39] based on data published by
Hautmann and Windisch [40,41] indicating an increased respi-
ratory load. There was a significant negative correlation between
body weight and vital capacity (R =20.42, p,0.001), FEV1
(R =20.49, p,0.001), MEF25 (R20.30, p= 0.009) (Fig. 2) and
FEV1/VC (R = 0.37, p= 0.001). Body weight (R = 0.32, p = 0.02)
(Figure 2) and body fat (R = 0.316, p = 0.03) was positively
correlated to P0.1. FEV1 and MEF25 were negatively correlated
to body fat. We found a significant negative correlation of waist-to-
hip-ratio with vital capacity (R =20.43, p,0.001) and with total
lung capacity (R =20.34, p = 0.003).
Echocardiographic data at baseline are shown in table 2. We
found an increased left and right myocardial performance index
compared to the normal values proposed by the American (ASE)
and European Society of Echocardiography (ESE) [43] that are
not weight specific. e/e’ was increased compared to these normal
values indicating diastolic dysfunction of the right ventricle. Mean
diameter of the interventricular septum and posterior wall of the
left ventricle were mildly enlarged in comparison to the normal
values recommended by ASE and ESE published by Lang et al
[42]. However, diameter of all cardiac chambers, ejection fraction,
mitral flow pattern and tissue Doppler parameter of the left
ventricle were normal.
We found a positive correlation between body weight and
myocardial wall thickness (IVSd, R = 0.37, p = 0.007; LPWd
(R = 0.42, p=0.002), body weight and left myocardial perfor-
mance index (R = 0.30, p= 0.04) and body weight and right atrial
area (R = 0.37, p = 0.006), (Figure 3). Waist-to-hip ratio was
positively correlated with myocardial wall thickness (IVSd,
R = 0.66, p,0.001) and acceleration time in the right ventricular
outflow tract (R =20.34, p = 0.02; Figure 3).
Follow-Up data
Follow-up data and absolute changes from baseline are shown
in table 3. After 4 months of the dietary program, body weight
decreased dramatically (226.0611.8 kg, p,0.001), as well as BMI
Figure 1. Subject selection for the analysis.
doi:10.1371/journal.pone.0107480.g001
Table 1. Anthropometric data.
Parameter N=74, Value Mean ± SD
Anthropometric data
female/male 74 32/42
Age (years) 74 43612
BMI (kg/m2) 74 42.567.9
Body weight (kg) 74 123.7624.9
Waist/hip ratio 74 0.9460.1
Systolic blood pressure 74 133614
Diastolic blood pressure 74 8969
Heart rate 74 7369
NYHA Class I/II/III/IV 74 68/6/0/0
Data are shown as mean 6 standard deviation.
doi:10.1371/journal.pone.0107480.t001
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(28.963.8, p,0.001) and body fat (218.567.7, p,0.001).
Table 3 shows the significant increase of lung volumes measured
by bodyplethysmography and spirometric flow parameters. P0.1/
Pimax decreased indicating improving breathing capacity.
The change of vital capacity (R =20.35, p 0.03) and FEV1
(R =20.44, ,p 0.01) negatively correlated with the change of
body fat. (Figure 4). The change of FEV1 (R = –0.31, p = 0.03)
(Figure 4), but not of vital capacity was correlated to the change of
body weight.
Additionally we noticed a decrease of myocardial wall thickness
(20.0860.20 cm, p= 0.02), an improvement of left ventricular
myocardial performance index (20.1660.35, p= 0.02), and mitral
annular plane systolic excursion MAPSE (+0.14 cm60.36,
p=0.03). Pulmonary outflow acceleration time increased (AT +
26.6 ms641.3, p=0.001) indicating a decrease of pulmonary
vascular resistance.
The decrease of myocardial wall thickness and the improvement
of left myocardial performance index were positively correlated
with the decrease of body weight (Figure 5).
Furthermore, the subjects with a history of asthma (n = 5)
showed an absolute increase of FEV1 (+13.8%, p,0.001). An
absolute decrease of residual volume (RV) of 215.8% led to an
absolute increase of VC (+10.6%, p = 0.005). Due to the increase
of FEV1 and VC the absolute increase of FEV1/FV (+1.1%,
p = 0.6) was not significant (Table S3).
The patients with OSA showed an absolute increase of FEV1 (+
12.3%, p = 0.02) and VC (+10.3%, p = 0.007). P 0.1 decreased
absolutely from 0.34 kPa to 0.26 kPa and P 0.1/Pi max from 0.06
to 0.04. Due to the small sample size (n = 2) the difference did not
reach significance (Table S3).
The subgroup analysis of the pooled subjects with cardiocircu-
latory conditions (arterial hypertension n = 23, chronic heart
failure n = 1, coronary artery disease n = 1) showed an absolute
Figure 2. Correlations of body weight with pulmonary function. VC= vital capacity. FEV1= forced expired volume at one second. MEF
25 =Mean expiratory flow 25. P 0.1 =mouth occlusion pressure at 0.1 second.
doi:10.1371/journal.pone.0107480.g002
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increase of FEV1 (+11.6%, p,0.001), VC (+7.5, p,0.001), FEV1/
VC (+3.0, p = 0.046) and an absolute increase of P 0.1 (+0.07 kPa,
p = 0 006) (Table S3).
Discussion
There is no doubt that obesity is associated with a large variety
of diseases including cardiopulmonary dysfunction [46,47], and is
a major contributor to morbidity [2,3] and mortality [3,4,46].
However, surprisingly little is known about the influence of obesity
on cardiac and pulmonary function in obese individuals who have
none or very mild symptoms. Importantly, it is unclear whether
dietary weight loss programs lead to improved cardiopulmonary
function similar to what has been reported for surgical weight loss
programs [34].
The study cohort consisted of severely obese individuals the
majority presenting asymptomatic in NYHA Class I without
dyspnea. Although some subjects had comorbidities such as
arterial hypertension, diabetes and dyslipidemia, which may have
contributed to the increase in LV wall thickness, they had no
obvious end organ damage. In our cohort we detected functional
pulmonary and cardiac abnormalities at baseline which signifi-
cantly improved after weight loss.
Obesity can lead to OHS and contribute to elevated pulmonary
artery pressure in OHS. However, not all obese subjects develop
OHS [12] and not all patients with OHS show PH [13]. Although
in our cohort maximal inspiratory mouth pressures was normal
[38,39] and there was only a mild decrease of airflow the subjects
showed an impairment of P 0.1 and P0.1/Pi max [38,39]. The
increased P0.1 and P0.1/Pi max in asymptomatic subjects
highlights the increased respiratory load early on in obese subjects.
The results are in line with data reporting abnormal breathing
patterns in obese subjects with no history of pulmonary disease
[15]. Despite the mild changes of ventilatory parameters at
baseline the correlation of improving VC and FEV1 with loss of
body fat further strengthens the assumption that obesity has a
major impact on ventilatory function in these individuals.
Although an association of asthma and overweight has been
proposed [17,18], there is still an ongoing debate on the degree of
the interaction between obesity and asthma [21,30]. Our subjects
Table 2. Baseline data: Bodyplethysmography including mouth occlusion pressure and echocardiography.
N Baseline (Mean ± SD)
Bodyplethysmography
VC (% pred.) 74 100.4615.6
FEV1 (% pred.) 74 99.8617.7
FEV1/VC (%) 74 79.267.7
MEF 25 (% pred.) 74 71.9628.6
ITGV (% pred.) 74 91.2616.5
RV (% pred.) 74 102.1632.7
TLC (% pred.) 74 102.0612.2
TLC-He (% pred) 30 90.0611.0
SR tot (% pred.) 74 109.1663.5
TLCO SB (% pred.) 47 87.3614.0
P0.1 (kPa) 51 0.2860.13
PI max (kPa) 36 6.862.9
P0.1/PI max 29 0.0560.05
BF (1/min) 35 18.065.5
Echocardiography
IVSd (mm) 54 10.962.5
LVPWd (mm) 54 10.662.3
EF biplan Simpson (%) 53 63.167.2
LIMP 46 0.5460.28
MAPSE (cm) 51 1.860.4
E/E’ 54 6.7461.67
TAPSE (mm) 54 28.865.1
RIMP 51 0.4060.22
RA area (cm2) 54 13.965.5
RV (cm) 54 3.2 0.7
e/e’ 51 4.8261.67
TDI-TVA (cm/s) 51 14.563.0
RVSP (mmHg) 7 20.468.6
PV AccT (ms) 50 117.8629.6
Data are shown as mean 6 standard deviation.
doi:10.1371/journal.pone.0107480.t002
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showed a significant correlation of weight and body fat with
pulmonary functional impairment. The importance of body fat
distribution for ventilatory function has been described previously
[17]. Our subjects showed a correlation of waist-to-hip ratio with
vital capacity and TLC indicating a predominant role of central
obesity for ventilatory abnormalities.
Obesity has a high impact on cardiac morbidity and mortality
[1,4]. An association between obesity and pulmonary mortality has
also been proposed [46]. Cardiovascular disease [47], obstructive
sleep apnea [9] and hypoventilation syndrome [10] are associated
with obesity. Recent data suggest a contribution of obesity to the
development of hypoventilation associated severe pulmonary
hypertension [11], an independent influence of body weight on
pulmonary hypertension in diastolic left ventricular function [8]
and also obesity cardiomyopathy [6,7].
The evaluation of myocardial function in obese subjects needs
to differentiate hypercontractility [6,7] in early stages of obesity,
impaired left ventricular function in patients affected by manifest
cardiomyopathy and additional parameters of myocardial function
such as left and right myocardial performance index [48,49],
annular tissue velocity and annular valve flow parameters
reflecting diastolic function. Despite left ventricular ejection
fraction and TAPSE being normal, we found elevated left and
right myocardial performance index as an early sign of cardiac
(diastolic and systolic) functional distress [43,48,49]. Myocardial
wall thickness of the interventricular septum and posterior wall
was mildly enlarged [42]. Echocardiography in severely obese
individuals is difficult to perform, but all echocardiographic
procedures were performed by a highly experienced physician.
Due to absence of detectable tricuspid valve insufficiency, right
ventricular systolic pressure could not be estimated in the majority
of tests. However, right ventricular outflow acceleration time
(RVOT AT) could be measured in nearly all subjects. Therefore
RVOT AT is a helpful non-invasive parameter for a qualitative
analysis of pulmonary blood flow and its reduction is associated
with decreasing pulmonary artery pressure and vascular resistance
[50]. The acceleration time of the right ventricular outflow tract
was mildly decreased in our cohort, suggesting the presence of
increased pulmonary artery pressure and pulmonary vascular
resistance [50].
The positive correlation of myocardial wall thickness and the
negative correlation of pulmonary outflow tract acceleration time
with the waist- to-hip ratio suggest an influence of central obesity
on cardiac function and pulmonary perfusion. The morphological
cardiac and functional cardiopulmonary changes may have been
mild, but the improvement of these parameters as well as the
correlation of weight and body fat loss with myocardial wall
thickness and improvement of myocardial performance index
highlight the clinical significance of the results. The correlation
between decreased body fat and improved vital capacity and FEV1
following weight loss further suggests that the abnormalities are
part of an early pathophysiological process leading ultimately to
disease in obese individuals.
Figure 3. Correlations of body weight with cardiac function and myocardial wall thickness. LVPWd=diastolic left ventricular posterior
wall diameter; IVSd= diastolic interventricular septal wall thickness; LIMP= left myocardial performance index; RVOT AccT = acceleration time of flow
in the right ventricular outflow tract.
doi:10.1371/journal.pone.0107480.g003
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Weight loss is strongly recommended for patients with obesity
related diseases such as obstructive sleep apnea [51,52], but the
effect of early intervention on lung and cardiac function in
asymptomatic obese subjects is less clear. It has previously been
shown that surgical induced weight loss has positive effects on
cardiac function [31,53,54,55,56]. Syed reported a decrease of
myocardial mass, but no significant improvement of functional
parameters following a structured program combining diet,
Table 3. Baseline and follow-up data, absolute changes and p values.
N
Baseline
(Mean ± SD)
Follow-Up
(Mean ± SD)
abs. change
(Mean ± SD) p-value
Weight, Height and Waist to hip ratio
Weight (kg) 55 125.6624.5 99.6617.9 226.0611.8 ,0,001
BMI (kg/m2) 55 43.468.1 34.566.3 28.963.8 ,0,001
WHR 62 0.9360.11 0.9060.09 20.0360.1 ,0,001
Bodyplethysmography
VC (% pred.) 51 98.5615.7 104613.7 +5.567,5 ,0,001
FEV1 (% pred.) 51 97.7618.8 107.5617.4 +9.868.3 ,0,001
FEV1/VC (%) 50 78,968.4 80.967.9 +2.064.9 0,006
MEF 25 (% pred.) 51 68.7629,008 82.3630.5 +13.6620.6 ,0,001
ITGV (% pred.) 51 90.6617.2 107.0621.0 +16.4616.0 ,0,001
RV (% pred.) 50 100.6632.9 87.2638.0 213.4635.4 0,01
TLC (% pred.) 51 100.78612.1 101.1612.1 +0,25611.0 0,86
SR tot (% pred.) 51 110.7663.0 93.3636.6 217.4641.5 ,0,01
TLCO SB (% pred.) 32 89.7613.1 91.84613.2 +2,2610.5 0,26
TLCO/VA (% pred.) 32 106.2613.8 101.9613.1 24.369.7 0,018
TLC-He (% pred.) 30 89.9610.6 95.2610.0 +5.366.0 ,0,001
P0.1 (kPa) 35 0.3160.12 0.2360.11 20.0761.0 ,0,001
PI max (kPa) 36 6.963.0 7.262.4 +0.362,3 0.59
P0.1/PI max 29 0.0660.05 0.0460.03 20.0260.05 ,0.01
BF (1/min) 35 19.165.8 18.264.6 20.965.5 0.35
Echocardiography
IVSd (cm) 35 1.0560.23 0.9760.18 20.0860.20 0.02
LVPWd (cm) 35 1.0560.24 0.9760.19 20.0860.20 0.03
EF biplan Simpson (%) 35 6466.8 62.967.2 21.0669.2 0.5
LIMP 27 0.6160.32 0.4560.31 20.1660.35 0.02
MAPSE (cm) 34 1.8160.35 1.9560.40 +0.1460.36 0.03
LVEI 34 0.9660,09 0,9360.10 20.0360.10 0,09
e/e’ 35 5.0761.81 4.7661.19 20.3161.48 0,22
TDI-TVA (cm/s) 35 14.362.9 13.162.62 21.263.1 0,03
RVSP (mmHg) 2 28.3611.7 20.564.5 27.866.7 0,35
PV AccT (ms) 31 123.0629.4 149.6637.9 +26.6641.3 0,001
BIA measurements
Resting metabolic rate (Kcal) 49 17506295 15546171 21956197 ,0,001
Phase angle (u) 49 5.9960.75 5.3660.86 20.6360.99 ,0,001
Body fluid (l) 49 50.6611.4 45.168.5 25,564,2 ,0,001
Lean body mass (kg) 49 69.1615.6 61.7611.6 27.465.8 ,0,001
ECM (kg) 49 33.267.1 32.067.3 21.262.5 0,002
BCM (kg) 49 35.969.3 29.765.4 26.266.2 ,0,001
ECM/BCM-Index 49 0.9460.13 1.0860.18 +0.1460.19 ,0,001
Cell amount (%) 49 51.763.6 48.464.3 23.364.7 ,0,001
Body fat (kg) 49 57.4616.6 38.9615.3 218.567.7 ,0,001
Body fat (%) 49 45.168.0 37.869.6 27.364.9 ,0,001
Body fat corr. (kg) 49 59.1616.6 37.8614.6 221.367 ,0,001
Data are shown as mean 6 standard deviation. This table shows data of subjects with corresponding data at both timepoints, baseline and follow-up examination.
doi:10.1371/journal.pone.0107480.t003
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exercise and surgical procedures. However, in this study left
myocardial performance index and acceleration time in the right
ventricular outflow tract was not investigated [34]. There are only
few reports on dietary induced weight loss and its effect on cardiac
and pulmonary function. Reduction of body fat improved lung
function after a Mediterranean diet [32]. A modest improvement
of lung volumes at rest after a moderately successful dietary weight
loss was shown and a relationship with the amount of chest fat was
discussed [33].
In our study, the participants achieved a remarkable weight loss,
that was substantially higher than in previous reports [32,33]
leading to a highly significant increase in lung volumes, ventilatory
flow parameters and a decrease of respiratory load. We found
significant improvement of early indicators of disturbed myocar-
dial performance such as LIMP and MAPSE. Additionally our
subjects had an improvement of myocardial wall thickness
following successful weight loss. We noticed an improvement of
the RVOT AT following weight loss in our study subjects. This
may indicate reduced pulmonary vascular resistance and im-
proved blood flow following a dietary induced weight loss.
Our cohort consisted of asymptomatic or almost asymptomatic
obese patients. There were only few patients with relevant
comorbidities. Subjects with a history of asthma and sleep apnea
showed an improvement of pulmonary function comparable to the
improvement of the whole cohort. The lack of significance of
FEV1/FVC in the asthmatics is the result of an increase of FEV1
and vital capacity and of the small sample size of subjects with
comorbidities. Although there is a clear signal towards an
Figure 4. Correlations of changes of pulmonary function with changes of body weight and changes of body fat and change of
FEV1/VC from baseline to follow-up. a–c: Correlations of changes of pulmonary function with changes of body weight and changes of body fat
(a–c) d: Change of FEV1/VC (%) ratio from baseline to follow-up (d), (data as mean 6 SD), p = 0.006. VC= vital capacity. FEV1= forced expired volume
at one second.
doi:10.1371/journal.pone.0107480.g004
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improvement of lung function in the few subjects with a history of
asthma and OSA and cardiocirculatory conditions, this should be
investigated in further studies especially addressing subjects with
comorbidities.
Our study has several limitations. Not all subjects seen at
baseline were examined after the weight loss program, but only
patients with data available at both baseline and three month
follow-up period were included into the analysis of changes in each
parameter. Bioelectrical impedance analysis was not performed in
all patients. However, the robustness of our data still suggest that
asymptomatic individuals without end organ damage entering a
structured weight loss program show mild cardiac and pulmonary
functional impairment associated with weight and body fat. This
can be reversed solely by a structured dietary induced weight loss.
Conclusion
In a cohort of severely obese asymptomatic adults we found
evidence for early functional pulmonary and cardiac distress. Lung
volumes and left ventricular myocardial performance index were
negatively correlated to body weight. Airway flow is negatively and
respiratory load is positively correlated to body fat. Myocardial
wall thickness is positively correlated to body weight. Right
ventricular outflow tract acceleration time and myocardial wall
thickness is correlated to waist-to-hip ratio. A structured dietary
program resulted in significant improvement of ventilatory and
myocardial parameters in these obese individuals strongly
suggesting that aggressive weight loss programs as early as possible
may be able to prevent cardiopulmonary morbidity.
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Figure 5. Correlations of changes of left myocardial perfor-
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body weight. LIMP = left myocardial performance index.
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